Olivier Danos is joining Regenxbio (NASDAQ: [[ticker:RGNX]]) to become the company’s chief scientific officer. Danos comes to the Rockville, MD, gene therapy biotech from Cambridge, MA-based Biogen (NASDAQ: [[ticker:BIIB]]), where he was the senior vice president of cell and gene therapy. Before joining Biogen, Danos was the senior vice president of molecular medicine, synthetic biology, and gene regulation at Kadmon Pharmaceuticals.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
